Roche has agreed to a $5.3 billion deal with Zealand Pharma to develop the obesity drug candidate petrelintide, including a fixed-dose combination with Roche’s CT-388, aiming to compete in the weight loss drug market. Zealand Pharma will receive $1.65 billion upfront and potential milestone payments, with shares of both companies rising after the announcement. The partnership will see Roche and Zealand jointly commercialize petrelintide in the U.S. and Europe, sharing profits and losses equally, while Roche will have exclusive commercialization rights in the rest of the world.
Full Article
Auckland Crips member Harley Eruti gets prison time for robbery, bail scam
Gang member Harley Davidson Eruti was sentenced to three years and three months in jail for attempting to pervert justice by faking a funeral to gain compassionate bail. This scheme followed a similar successful attempt by a co-defendant, who had used the same funeral home and was released for a godmother's funeral but failed to return. Judge Ngaroma Tahana acknowledged Eruti's efforts to change but highlighted his serious criminal history, leading to the court's decision...
Read more